



Amylin Pharmaceuticals, Inc.
 9360 Towne Centre Drive
 San Diego, CA 92121 USA

Tel (858) 552 2200
 Fax (858) 552 2212
 www.amylin.com

Schedule of Selected Presentations
70th Scientific Sessions of the American Diabetes Association
June 25-29, 2010 | Orlando, FL

Educational Symposia		Presentation Details
ADA Symposia Session	Looking Beyond Glucose Control in Type 2 Diabetes—The Cardiovascular, Cardioprotective, and Weight Effects of GLP-1 Faculty: Patrick J. Boyle, MD; Ralph A. DeFronzo, MD; Carol H. Wysham, MD Sponsored by Purdue University School of Pharmacy and MediKinetics, LLC. Supported by unrestricted educational grants from Amylin Pharmaceuticals, Inc. and Lilly USA, LLC	Saturday, June 26, 2010 5:30 PM – 9:30 PM Dinner served at 5:30 PM Rosen Centre Hotel Grand Ballroom
ADA Symposia Session	Diabetes Close to the Heart; A Comprehensive Approach to Managing Type 2 Diabetes Hosted by Steven Edelman, MD Panel: Louis Aronne, MD; Stephen Brunton, MD; Robert Chilton, DO; Steven Edelman, MD; Davida Kruger, MSN Sponsored by Amylin Pharmaceuticals, Inc.	Sunday, June 27, 2010 6:00 PM – 10:00 PM Reception 6:00 PM Play Premiere and Panel Discussion 7:00 – 9:00 PM Rosen Centre Hotel Junior Ballroom
Joint ADA/The Lancet Symposium	Efficacy and Safety of Exenatide Once Weekly Versus Sitagliptin or Pioglitazone as an Adjunct to Metformin for Treatment of Type 2 Diabetes (DURATION-2): A Randomized Trial, <i>Bergental, R.</i>	Saturday, June 26, 2010 8:40 AM – 9:00 AM Valencia Ballroom AB Convention Center
Joint ADA/The Lancet Symposium	Once Weekly Exenatide Compared with Insulin Glargine Titrated to Target in Patients with Type 2 Diabetes (DURATION-3)—An Open-Label Randomized Trial, <i>Diamant, M.</i>	Saturday, June 26, 2010 9:00 AM – 9:20 AM Valencia Ballroom AB Convention Center
Selected Presentations Related to Exenatide		
Oral 61-OR	Safety and Tolerability of Exenatide Once Weekly Pooled Summary of 1095 Patients From DURATION-1, 2, and 3, <i>Lee, D.</i>	Saturday, June 26, 2010 8:45 AM-9:00 AM Convention Center
POSTER PRESENTATIONS: All posters are displayed from Saturday, June 26th (10 AM) through Monday, June 28th (4 PM).		
Poster 1627-P	Exenatide Attenuated Chemically-Induced Pancreatitis in Diabetic <i>ob/ob</i> Mice Following 4-Week Infusion, <i>Tatarkiewicz, K.</i>	Saturday, June 26, 2010 11:30 AM – 1:30 PM Convention Center
Poster 1633-P	Exenatide Did Not Affect Pancreatic Exocrine Secretion in a Sodium Taurocholate Model of Acute Pancreatitis, <i>Villescaz, C.</i>	Saturday, June 26, 2010 11:30 AM – 1:30 PM Convention Center
Poster 1294-P	Economic Evaluation of Patients With Type 2 Diabetes Who Initiated Exenatide or Glargine, <i>Pawaskar, M.</i>	Sunday, June 27, 2010 12:00 – 2:00 PM Convention Center
Late Breaking Poster 8-LB	DURATION-5: Exenatide Once Weekly Results in Significantly Greater Improvements in Glycemic Control With Less Nausea Than Exenatide Twice Daily in Patients With Type 2 Diabetes, <i>Blevins, T.</i>	Monday, June 28, 2010 12:00 – 2:00 PM Convention Center
Late Breaking Poster 10-LB	Exenatide Added to Insulin Glargine-Treated Patients With Type 2 Diabetes Achieved Glycemic Targets and Weight Loss With No Increased Risk of Hypoglycemia, <i>Buse, J.</i>	Monday, June 28, 2010 12:00 – 2:00 PM Convention Center
Poster 543-P	Incidence and Relative Incidence of Medical Record Confirmed Acute Pancreatitis: Exenatide Initiators Compared to Other Antidiabetic Drug Initiators, <i>Noel, R.</i>	Monday, June 28, 2010 12:00 – 2:00 PM Convention Center
Poster 557-P	Effects of Exenatide Vs. Insulin Aspart on Glycemic Control and Hypoclycemia in Diabetes Patients Treated With Metformin: Primary Results of an Randomized, Open-Label Study, <i>Gallwitz, B.</i>	Monday, June 28, 2010 12:00 – 2:00 PM Convention Center

Selected Presentations Related to Exenatide

POSTER PRESENTATIONS: All posters are displayed from Saturday, June 26th (10 AM) through Monday, June 28th (4 PM).

Poster 582-P	Treatment With Once-Weekly Exenatide for 52 Weeks Resulted in Improvements in Glycemic Control, Body Weight, and Markers of Cardiovascular Risk and Hepatic Injury, <i>Horton, E.</i>	Monday, June 28, 2010 12:00 – 2:00 PM Convention Center
Poster 592-P	Modeling Cardiovascular Health Outcomes Associated With Once-Weekly Exenatide Versus Traditional Therapies for Type 2 Diabetes, <i>Peskin, B.</i>	Monday, June 28, 2010 12:00 – 2:00 PM Convention Center
Poster 594-P	DURATION-2: Effect of Switching to Once Weekly Exenatide From Maximum Daily Doses of Sitagliptin or Pioglitazone, <i>Wysham, C.</i>	Monday, June 28, 2010 12:00 – 2:00 PM Convention Center
Poster 596-P	A Retrospective Cohort Study to Assess the Relative Risk of Acute Pancreatitis Among Initiators of Exenatide Compared to Initiators of Other Antidiabetic Medication: A Follow-up Study, <i>Wenten, M.</i>	Monday, June 28, 2010 12:00 – 2:00 PM Convention Center
Poster 597-P	Once-Weekly Exenatide Used for 6 Months Provided Both Improved Glycemic Control and Weight Loss Compared to Sitagliptin, Pioglitazone, or Insulin Glargine in Metformin-Treated Patients With Type 2 Diabetes, <i>Horton, E.</i>	Monday, June 28, 2010 12:00 – 2:00 PM Convention Center
Poster 644-P	Bone Mineral Density Was Not Affected by Exenatide Therapy Despite a Significant Reduction in Body Weight in Patients With Type 2 Diabetes, <i>Eliasson, B.</i>	Monday, June 28, 2010 12:00 – 2:00 PM Convention Center
Poster 664-P	Dynamics of Weight Change and Glycemic Control in Patients With Type 2 Diabetes Treated With Exenatide or Insulin, <i>Paul, S.</i>	Monday, June 28, 2010 12:00 – 2:00 PM Convention Center
Poster 673-P	Exenatide Observational Study (ExOS): Results of 6-Month Primary and Secondary Endpoint Effectiveness Analysis, <i>Bergenstal, R.</i>	Monday, June 28, 2010 12:00 – 2:00 PM Convention Center
Poster 674-P	Exenatide Resulted in Significantly Greater Improvements in 24h Average Glucose Compared to Sitagliptin in Patients With Type 2 Diabetes, <i>Holcombe, J.</i>	Monday, June 28, 2010 12:00 – 2:00 PM Convention Center
Poster 683-P	Improved Glycemic Control and Reduced Body Weight with Exenatide Twice Daily: A 24-week, Double-Blind, Randomized, Placebo-Controlled, Parallel, Phase 3 Study in Japanese Patients with Type 2 Diabetes, <i>Imaoka, T.</i>	Monday, June 28, 2010 12:00 – 2:00 PM Convention Center
Poster 712-P	Risk of Cardiovascular Events in Patients With Diabetes Treated With Exenatide or Other Glucose-Lowering Therapies: A Retrospective Analysis of the LifeLink Database, <i>Best, J.</i>	Monday, June 28, 2010 12:00 – 2:00 PM Convention Center
Poster 715-P	Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Treated With a Thiazolidinedione, <i>Norwood, P.</i>	Monday, June 28, 2010 12:00 – 2:00 PM Convention Center
Poster 728-P	Three-Year Exenatide Therapy, Followed By a 4-Week Off-Drug Period, Had a Sustainable Effect on β -cell Disposition Index in Metformin Treated Patients With Type 2 Diabetes, <i>Bunck, MC.</i>	Monday, June 28, 2010 12:00 – 2:00 PM Convention Center

Selected Presentations Related to Pramlintide

POSTER PRESENTATIONS: All posters are displayed from Saturday, June 26th (10 AM) through Monday, June 28th (4 PM).

Poster 647-P	Cardiovascular Safety of Pramlintide: a Meta-Analysis of 5 Controlled Clinical Trials in Patients With Type 2 Diabetes, <i>Chen, S.</i>	Monday, June 28, 2010 12:00 – 2:00 PM Convention Center
--------------	---	---

Selected Presentations Related to Programs in Development

Oral 280-OR	Enhanced Amylin-Mediated Weight Loss in Ovariectomized Rats is Associated With Increased Metabolism and Does Not Require Intact Leptin Signaling, <i>Roth, J.</i>	Sunday, June 27, 2010 5:00 - 5:15 PM Convention Center
-------------	---	--

Investor Program

Reception and Presentation	Amylin will webcast a presentation to the investment community highlighting information presented at the conference.	Sunday, June 27, 2010 Doors Open 6:30 PM Webcast begins 7:30 PM Doubletree Resort
----------------------------	--	---